Reprogramming temozolomide response in glioblastoma through regulated and immunogenic cell death modalities
{{output}}
Temozolomide (TMZ) resistance, driven by genetic, epigenetic, and tumor microenvironment factors, remains a significant barrier in glioblastoma (GBM) therapy. Immunogenic cell death (ICD) modalities (such as necroptosis, ferroptosis, pyroptosis) offer a promis... ...
